Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
NCT04498377 · EVIVE Biotechnology · PHASE2 · terminated · last registry update 2023-12-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “There have been significant changes in the FDA guidelines and clinical standard of care” | – | Registry record, EVIVE Biotechnology |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL10RB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-05-23Also stopped (withdrawn): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Peginterferon Lambda (NCT05953545)
- 2023-10-02Also stopped (withdrawn): EVIVE Biotechnology, F-652 + Placebo (NCT05205668)
- 2023-06-13Results posted on the registry: Bristol-Myers Squibb, Pegylated Interferon Lambda-1a + Daclatasvir (DCV) (NCT01866930)
- 2023-06-13Also stopped (terminated): Bristol-Myers Squibb, Pegylated Interferon Lambda-1a + Daclatasvir (DCV) (NCT01866930)
- 2023-01-17Results posted on the registry: EIT Pharma, Inc., Peginterferon Lambda-1A (NCT02765802)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision